BioCentury
ARTICLE | Finance

Risk/benefit uncertainty

Intercell shares slide after enrollment in S. aureus vaccine trial suspended

April 18, 2011 7:00 AM UTC

A potential safety signal and/or minimal efficacy are possible culprits in last week's suspension of enrollment in a Phase II/III trial of Intercell AG's V710 to prevent Staphylococcus aureus infections.

Shares of Intercell (VSE:ICLL; OTCQX:INRLY) slid €2.32 (28%) to €5.88 last Monday on the news that an independent data monitoring committee (DMC) stopped the trial...